



## **Idera Pharmaceuticals to Present at Upcoming Investor Conferences**

July 30, 2008 12:01 PM EDT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 30, 2008--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biopharmaceutical company focused on developing therapeutics targeting Toll-Like Receptors (TLR), today announced that it will discuss its TLR-targeted drug discovery and development programs and provide a general corporate overview at the following conferences:

- BMO Capital Markets Focus on Healthcare Conference, on Wednesday, August 6, 2008 at 10:45 a.m. (EDT) at the Millennium Broadway Hotel in New York City.
- Canaccord Adams 28th Annual Global Growth Conference, on Thursday, August 14, 2008 at 11:00 a.m. (EDT) at the Intercontinental Hotel in Boston.

The presentations will be available via live audio webcast on the Company's website at [www.iderapharma.com](http://www.iderapharma.com). Archived replays will also be located on the Company's site following the event.

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances. For more information, visit [www.iderapharma.com](http://www.iderapharma.com).

### **Idera Forward Looking Statements**

This press release contains forward-looking statements concerning Idera Pharmaceuticals, Inc. that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "estimates," "intends," "should," "could," "will," "may," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Idera's actual results to differ materially from those indicated by such forward-looking statements, including whether products based on Idera's technology will advance into or through the clinical trial process on a timely basis or at all and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if the Company's products receive approval, they will be successfully distributed and marketed; whether Idera's cash resources will be sufficient to fund the Company's operations; and such other important factors as are set forth under the caption "Risk Factors" in Idera's Quarterly Report on Form 10-Q filed on May 12, 2008, which important factors are incorporated herein by reference. Idera disclaims any intention or obligation to update any forward-looking statements.

CONTACT: Idera Pharmaceuticals, Inc.  
Kelly Luethje, 617-679-5519  
[kluethje@iderapharma.com](mailto:kluethje@iderapharma.com)  
or  
MacDougall Biomedical Communications  
Chris Erdman, 781-235-3060  
[cerdman@macbiocom.com](mailto:cerdman@macbiocom.com)

SOURCE: Idera Pharmaceuticals, Inc.